Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

  • HOME
  • BROWSE ARTICLES
  • Previous issues
19
results for

Previous issues

Article category

Keywords

Previous issues

Prev issue Next issue

Volume 7(2); June 2001

Review

Ten Golden Rules of Fluid Therapy
Man S . Oh
Korean J Hepatol 2001;7(2):135-139.
  • 3,344 View
  • 19 Download

Original Articles

Renal Function Indices Predicting the Prognosis o f Patients with Liver Cirrhosis
Jeong Ihn Seo, M.D., Soon Koo Baik, M.D., Jae Woo Kim, M.D., Dae Wook Rhim, M.D., Yong Soon Park, M.D., Hyun Soo Kim, M.D., Dong Ki Lee, M.D., Sang Ok Kwon, M.D., and Sei Jin Chang, Ph.D.*
Korean J Hepatol 2001;7(2):140-146.
Background/Aims
Renal dysfunction commonly develops in patients with established liver disease. The assessment of renal function is of clinical importance in patients with cirrhosis and ascites. Renal function indices such as glomerular filtration rate and the plasma renin activity (PRA) could be better predictors of survival than the parameters usually used to estimate liver function including Child-Pugh score. This study was designed to find whether renal function indices are useful in determining the prognosis concerned with the survival of patients with liver cirrhosis.Methods:A total of 110 patients was selected and followed for 89 weeks. As indices reflecting renal function, creatinine clearance rate, PRA, aldosterone concentration, and the pulsatility index (PI) and resistive index (RI) by Doppler ultrasonography were measured. The prognostic values of these indices were determined by comparison and analysis according to survival or death of the patients. For the statistics, univariate and multivariate analysis was done.Results:Child-Pugh score (≥10), creatinine clearance rate (<80 mL/min), plasma alodosterone concentration (≥15 ng/dL), PRA (≥8 ng/mL/hr), renal PI (≥1.15) and RI (≥0.7) were prognostic indicators in univariate analysis (p<0.05). Multivariate analysis disclosed two independent survival predictors of creatinine clearance rate (<80 mL/min) (OR:5.37, 95% CI: 2.09-13.82) and plasma aldosterone concentration (≥15 ng/dL) (OR: 3.65, 95% CI: 1.09-12.18). Conclusion:Various renal function indices are closely related to the survival of patients with liver cirrhosis. Creatinine clearance rate and plasma aldosterone concentration are especially important prognostic factors in predicting the survival of patients with liver cirrhosis.(Korean J Hepatol 2001;7:140-146)
  • 4,000 View
  • 15 Download
Hepatic Zinc Concentration in Patients with Chronic Viral Hepatitis
Jeong Yeol Kim, M.D., Ji Hyun Moon, M.D.*, Kyong Duk Suh, M.D., Jae seung Lee, M.D., Hyung Jun Chu, M.D., Dae Hwan Kang, M.D., Geun Am Song, M.D., Mong Cho, M.D., Ung Suk Yang, M.D
Korean J Hepatol 2001;7(2):147-152.
Background and Aims
Zinc is an essential, mostly intracellular, trace element which participates in many oxidative or deoxidative reactions and in a protective action on liver cell activity. Plasma zinc levels are known to decrease in patients with liver disease including chronic viral hepatitis. The aim of this study was to reveal whether hepatic zinc concentrations have a correlation with grades of necroinflammation or stages of fibrosis in the patients with chronic viral hepatitis.Methods:This study consisted of 50 subjects (43 chronic hepatitis B, 4 chronic hapatitis C, and 3 cirrhosis). Each specimen of liver tissue was classified with the grade of lobular inflammation, portal/periportal inflammation, and stage of fibrosis according to Scheuer’s method. Hepatic zinc concentration was determined by ICP-Atomic Emission Spectrometry. Results:The mean hepatic zinc concentration in the 50 chronic viral hepatitis patients was 233.66 ?g/g dry weight of liver tissue. The hepatic zinc levels were significantly correlated with the grades of portal/periportal inflammation (rs=-0.385, p=0.006), and grades of lobular inflammation(rs=-0.342, p=0.015). The stages of fibrosis were also negatively related (rs=-0.423, p=0.002). The zinc concentrations differed significantly among grades of lobular inflammation (p=0.013) and among stages of fibrosis (p=0.044). Conclusions:Hepatic zinc concentrations showed negative correlation with grades of portal/periportal inflammation, lobular inflammation, and stage of fibrosis in the patients of chronic viral hepatitis. These results suggest that decreased hepatic zinc concentration might be associated with severe hepatic injury and reflect decreased protective activity on liver cell injury. (Korean J Hepatol 2001;7:147-152)
  • 3,936 View
  • 16 Download
Clinical Significance of Autonomic Neuropathy in Liver Cirrhosis
Jae Hong Park, M.D., Sung Woo Jeon, M.D., Min Kyu Jung, M.D., Jong Hyub Lee, M.D., Chang Min Cho, M.D., Won Young Tak, M.D., Young Oh Kweon, M.D., Sung Kook Kim, M.D., Yong Hwan Choi, M.D., Joon Mo Chung, M.D., Ki Soo Park, M.D.*
Korean J Hepatol 2001;7(2):153-161.
Background/Aims
Autonomic neuropathy is not rare in patients with liver cirrhosis but little is known about the mechanisms and clinical characteristics of it. We evaluated the relationship between the severity of liver disease and that of autonomic neuropathy.Methods:Sixty patients with liver cirrhosis (age 53±8.4, mean±SD) were studied. Liver function and prothrombin time were tested and an ultrasonography or CT scan was performed. Liver function reservoir was classified according to Child-Pugh score for all patients. Heart rate variations in response to deep breathing, to Valsalva maneuver, and to orthostatism were also measured and were expressed by E/I index, Valsalva index, and Posture index, respectively. The prevalence was estimated and divided into early involvement and definite involvement using each index. The correlation between the severity of the liver disease and that of autonomic neuropathy was also studied.Results:Evidence of autonomic neuropathy was found in 68.3% (41); early involvement 46.7% (28), and definite involvement 21.7% (13), respectively. The prevalence of autonomic neuropathy was similar in alcohol induced, and virus induced, liver disease (84.6% vs 63.8%). Child-Pugh score showed inverse correlation with E/I index (r=-0.38, p<0.01) and Valsalva index (r=-0.34, p<0.05). On multiple logistic regression analysis, cardiovascular autonomic neuropathy was related to the serum albumin level (odds ratio 0.063, 95% CI). Conclusion:In liver cirrhosis the prevalence and the severity of cardiovascular autonomic dysfunction are related to the severity of hepatic dysfunction (Child-Pugh score). It is possible that this complication may be of prognostic significance in patients with liver cirrhosis.(Korean J Hepatol 2001;7:153-161)
  • 4,102 View
  • 16 Download
The Therapeutic Effects of Lamivudine and Detection of Mutations in YMDD Motif of Hepatitis B Virus Genome in Chronic Hepatitis B Patients
Mi Sung Kim, M.D., Hee Bok Chae, M.D., Ki Won Choi, M.D., Tae Won Lee, M.D., Seon Mee Park, M.D., Sei Jin Youn, M.D., Suk Chul Bae, Pharm. D.*
Korean J Hepatol 2001;7(2):162-170.
Background/Aims
Recipients, at 13 months after administration of daily doses of 100 mg of lamivudine, were likely to have the highest rate of HBeAg seroconversion (32%); the greatest suppression of HBV DNA (98% reduction at week 52); and the highest rate of sustained normalization of ALT levels (72%). In a 1-year trial of lamivudine for chronic hepatitis B patients, the incidence of YMDD mutations was known to be about 14%. We intend to determine the incidence of YMDD mutations and the correlation between the mutation of the virus and the clinical characteristics of the patient.Methods:Between Feb. 1999 and Sept. 2000 we conducted a prospective study. Patients received 100 mg of lamivudine per day orally for at least 9 months. The average period of follow-up was 15 months. The patients enrolled in this study were composed of 20 chronic hepatitis B patients and 3 liver cirrhosis patients. The male to female ratio was 18:5. The average age of the patients was 40 years. The HBV DNA was extracted from the initial serum and the serum on abnormal ALT level, and then PCR was done. Finally we sequenced a 459-bp fragment and analyzed which samples had YMDD mutation or did not.Results:(1) The genetic mutations in the YMDD locus occurred in 3 of the 23 patients (13%), two patients exhibited YIDD mutation, and one patient exhibited YVDD at 24, 52, 48 weeks of therapy respectively. (2) During the 3 months of treatment, serum ALT levels returned to normal in 13 of the 23 patients (56%). The HBV DNA disappearance rate at 3 and 8 months was 63% and 84% respectively. The 8 of 19 patients who lost the HBV DNA during lamivudine treatment experienced the breakthrough at about 13 months (the range: 8~27 months). 4 patients experienced HBeAg seroconversion during the treatment period (17%).Conclusions:The mutations in the YMDD motif, especially the YIDD type, may aggravate the clinical outcome of the patients. We concluded that the treatment duration should be prolonged with these patients.(Korean J Hepatol 2001;7:162-170)
  • 4,067 View
  • 14 Download
Efficacy of 1 - Year Lamivudine Treatment in the Patient of Chronic B Hepatitis and Liver Cirrhosis
Yong Song Kim,Seung Soo Kim,Hung Yong Jin,Myung Sin Ma,Seung Ok Lee,Soo Teik Lee,Dae Ghon Kim,Deuk Soo Ahn
Korean J Hepatol 2001;7(2):171-180.
Background/Aims
Lamivudine is highly effective in suppressing hepatitis B virus replication and hepatitis B induced necroinflammatory activity. The objective of this study was to evaluate the virological and biochemical responses to lamivudine by patients with HBV associated chronic liver disease. In particular we stressed the importance of lamivudine therapy by patients with decompensated liver cirrhosis.Methods:We conducted a one-year trial of lamivudine in 80 patients with HBV associated chronic liver disease (chronic hepatitis 44, cirrhosis 36). We classified these patients according to the severity of hepatic dysfunction as chronic B hepatitis (Group A) or liver cirrhosis (Group B). These patients were treated for 12 months with 100 mg daily doses of lamivudine.Results:The seroconversion rate of HBeAg was 23.5% in group A patients and 26.7% in group B patients. The negative conversion of HBV-DNA was sustained for one year in 79.5% of patients in group A and 86.1% in group B. The normalization rates of serum ALT were 90.9% in group A and 88.9% in group B patients. No serious side effect after discontinuance of the treatment was found. There were 12 ALT breakthrough cases and all of them showed mutation of YMDD motif. However, they did not deteriorate clinically in spite of ALT elevation and HBV-DNA reappearance. The Child-Pugh scores improved even in patients with decompensated liver cirrhosis.Conclusion:One-year lamivudine treatment resulted in excellent virological and biochemical improvements and was well tolerated in the patients with HBV associated chronic liver disease, even in decompensated cirrhosis. We conclude that lamivudine is relatively safe in chronic hepatitis B and liver cirrhosis treatment.(Korean J Hepatol 2001;7:171-180)
  • 3,382 View
  • 13 Download
Changes of Propranolol Pharmacokinetic Parameters According to Hepatic Fibrotic Severity in CCl4-Treated Rats
Mun Su Kang, M.D., Chang Ok Yoon, M.D., Jai Won Byun, M.D., Oh Young Lee, M.D. Byung Chul Yoon, M.D., Joon Soo Hahm, M.D., Ju Seop Kang, M.D.*, Min Ho Lee, M.D.
Korean J Hepatol 2001;7(2):181-188.
Background/Aims
This study was designed to determine the effect of hepatic fibrotic severity on pharmacokinetics of propranolol in CCl4-treated rats.Methods:1 mL/kg of 10% CCl4 in olive oil was injected intramuscularly to rats twice weekly for 4, 6, 8 and 10 weeks, respectively(n=6). Control(n=6) was a sham-injected equal dose of olive oil for 10 weeks. After intravenous bolus injection of 2 mg/kg propranolol to rats, the serum propranolol concentrations were analyzed for 4 hours at various time points by a HPLC-fluorimetric system, and pharmacokinetic parameters such as C0, MRT, AUC, Vdss, t1/2(β) and CLp were determined. Then, a small amount of hepatic tissue was obtained and subjected to determination of the hepatic 4-hydroxyproline content, which confirmed the hepatic fibrotic severity. Results:The serum concentrations of propranolol at 0.5, 1, 2 and 4 hours were significantly increased in CCl4-treated rats(p<0.01). In proportion to the duration of CCl4 treatment, C0 and AUC were significantly increased, and Vdss and CLp were significantly decreased(p<0.001). But MRT and t1/2(β) were not significantly changed. The hepatic 4-hydroxyproline content was gradually increased in CCl4-treated rats(p<0.001).Conclusion:Gradual changes in pharmacokinetic parameters of propranolol were seen to be dependent on the hepatic fibrotic severity. We suggest that gradual dosage modification, according to their hepatic fibrotic severity, is necessary for many drugs administered to patients with chronic liver disease.(Korean J Hepatol 2001;7:181-188)
  • 3,452 View
  • 17 Download

Case Reports

Liver Abscess Formation in Non - Tumorous Parenchyma after Transcatheter Arterial Chemoembolization (TACE) for the Treatment of Hepatocellular Carcinoma Associated with Pneumobilia
Yong Kyun Kim, M.D., Su Eun Yu, M.D., Chang Kyun Hong, M.D., Sung Ku Lee, M.D., Young Chul Kim. M.D., So Young Lee, M.D., Si Hyun Bae, M.D., Je Hyun Shin, M.D., Byung Hun Byun, M.D., Jong Young Choi, M.D., Young Min Park, M.D., Kyu Won Chung, M.D., Hee Sik Sun, M.D., Doo Ho Park, M.D., Boo Sung Kim, M.D., Yeon Joo Jung, M.D.†
Korean J Hepatol 2001;7(2):189-194.
Transcatheter arterial chemoembolization (TACE) is widely used to treat inoperable hepatocellular carcinoma and metastatic tumor of the liver. Among the complications occurring after TACE, liver abscess formation in HCC is a fatal complication. The reported incidence of this complication ranges from 0% to 3.3%. Moreover, liver abscess formation in non-tumorous parenchyma is very rare. The pathogenic mechanism of this complication has been linked to several factors but retrograde enteric bacterial contamination of the biliary tract appears to be the most commonly implicated cause. The major risk factors of the biliary tract infection are pneumobilia, portal vein thrombosis, bilo-enteric anastomosis and biliary obstruction. We report a rare case of liver abscess formation in non-tumorous liver parenchyma after TACE for the treatment of hepatocellular carcinoma in a patient with pneumobilia. (Korean J Hepatol 2001;7:189-194)
  • 4,205 View
  • 17 Download
A Case of Severe Chronic Active Epstein - Barr Virus Infection with Hepatic Involvement Confirmed by In Situ Hybridization
Tae Yoon Lee, M.D., Han Chu Lee, M.D., Tae Hoon Oh, M.D., Byung Cheol Song, M.D., Young-Hwa Chung, M.D., Yung Sang Lee, M.D., Eun Sil Yu, M.D.*, Chan Jung Park, M.D.†, Dong Jin Suh, M.D.
Korean J Hepatol 2001;7(2):195-200.
Epstein-Barr virus (EBV) infection is associated with diverse clinical manifestations. Hepatic involvement by EBV can cause a broad spectrum of histologic and clinical features ranging from acute hepatitis through lymphoproliferative disorders to lymphoma. However, severe chronic active EBV infection with hepatic involvement in adults is quite rare. EBV infection can be demonstrated by serologic test or molecular biologic techniques. In situ hybridization can demonstrate the EBV infection. It has the advantage of precise localization of the virus in infected tissues or tumors. Here we will describe a 46-year-old female who was admitted to our hospital because of general weakness, ready fatiguing, and jaundice. A bone marrow biopsy revealed reactive histiocytosis with hemophagocytosis. A liver biopsy revealed lymphocyte infiltration to portal areas and sinusoids, periportal and pericellular fibrosis, mild cholestasis, and micro-and macro-vesicular fatty change. Although the results of the serologic tests were inconclusive, in situ hybridization studies which were performed on liver biopsy tissue revealed the expression of Epstein-Barr virus-encoded RNA 1 transcripts in lymphocytes infiltrating to hepatic sinusids.(Korean J Hepatol 2001;7:195-200)
  • 3,570 View
  • 22 Download
Combined Hepatocellular and Cholangiocarcinoma , Separate Type - A Case Report
Ho Sung Park, Jeong Min Lee*, Hee Chul Yu†, Woo Sung Moon
Korean J Hepatol 2001;7(2):201-205.
Combined hepatocellular and cholangiocarcinoma (cHCC-CC) is an uncommon form of primary liver cancer having features of both hepatocellular and billiary epithelial differentiation. We report a case of cHCC-CC that separately developed in a patient who was serologically positive for hepatitis B virus. A 36-year-old woman was diagnosed by ultrasonography with an asymptomatic tumor in the left lobe of the liver. Based on radiologic and serologic findings of elevated serum alpha-fetoprotein (AFP) level, a preoperative diagnosis of hepatocellular carcinoma was made. A left lobectomy of the liver was done. On histological examination, the resected tumor was shown to consist of two separated masses. One was hepatocellular carcinoma that showed immunoreactivity for AFP. The other was cholangio- carcinoma that showed immunoreactivity for cytokeratin-19 (CK-19) in a separate form. (Korean J Hepatol 2001;7:201-205)
  • 3,641 View
  • 15 Download
Two Cases of Intrahepatic Biliary Cystadenoma
Chul Hee Yi, M.D., Neung Hwa Park, M.D., In Du Jung, M.D., Jong Ho Park, M.D., Jae Hyun Yoon, M.D., Dong Ha Han, M.D., Kwang Ro Ju, M.D., Do Ha Kim, M.D., Dae Woon Uhm, M.D.*, Jae Hee Suh, M.D.*
Korean J Hepatol 2001;7(2):206-212.
Biliary cystadenomas are very rare cystic neoplasms usually arising from the intrahepatic bile ducts. The majority of patients are middle-aged women who present with abdominal discomfort and/or a palpable mass. The diagnosis was performed using several methods such as abdominal ultrasonography, computed tomography, percutaneous cholangiography or endoscopic retrograde cholangiopancreatography, and showed multiloculated cystic tumors with multiple internal septation. But confirmatory diagnosis was done by surgical pathology. Because the prognosis is comparatively better than after complete resection and the cystadenoma is warranted to avoid malignant change, early detection and surgical resection must be needed. We have experienced two cases, 30 and 50 year old females, which presented with nonspecific abdominal pain and dyspepsia. They were diagnosed as having intrahepatic biliary cystadenoma histopathologically which was confirmed after surgical resection. We report two cases of intrahepatic biliary cystadenoma with a review of literature.(Korean J Hepatol 2001;7:206-212)
  • 3,877 View
  • 13 Download
A Case of Theophylline - Induced Hepatitis
Dae Wook Rhim, M.D., Soon Koo Baik, M.D., Yong Soon Park, M.D. Hark Cheon Park, M.D., Jeong Ihn Seo, M.D., Hyun Soo Kim, M.D., Won Yeon Lee, M.D., Suk Joong Yong, M.D., Kye Chul Sin, M.D., Dong Ki Lee, M.D., Sang Ok Kwon, M.D., Tae Heon Kim, M.D.*, Mee Yon Cho, M.D.*
Korean J Hepatol 2001;7(2):213-215.
Theophylline has been widely used in the treatment of asthma and chronic obstructive lung disease. To date, there have been very few reports on hepatotoxicity due to theophylline. We diagnosed, through biochemical testing and a liver biopsy, a case of acute cholestatic hepatitis developed after oral consumption of theophylline. A 43 year-old man was admitted to the department of internal medicine due to jaundice and pruritus which developed after ten days administration of oral theophylline(Etheophyl(R)). Liver function tests showed elevated serum bilirubin at 13.2 mg/dL with AST and ALT of 71 U/L and 194 U/L. Alkaline phosphatase and γ-GTP were also elevated at 175 U/L and 301 U/L. There was no evidence of viral or autoimmune hepatitis in laboratory tests. The patient’s symptoms and liver function tests were improved after conservative treatment. After 9 months oral theophylline was readministered for the control of relapsed asthma. Then, jaundice and pruritus again developed again. A liver biopsy showed a few lymphocytes and eosinophilic inflammatory cell infiltration in portal tract and cholestasis in the lobule. Drug-induced hepatitis was diagnosed with a typical clinical course; the exclusion of all possible causes of acute hepatic dysfunction; and a positive response to accidental readministration of drug. We report this case with a review of the literature.(Korean J Hepatol 2001; 7:213-215)
  • 4,383 View
  • 32 Download

Cyber Hepatology

Pathogenesis of Alcoholic Liver Injury and Internet Web Site
Jin Mo Yang
Korean J Hepatol 2001;7(2):216-219.
  • 3,077 View
  • 16 Download

Hepatology Elsewhere

만성 C형 간염 환자에 있어 건강관련성 삶의 질(HRQOL)의 감소에 대한 연구가 보고되고 있으며 이런 HRQOL의 감소는 간질환의 중증도와 관련이 없다고 알려져 있는데 이런 현상의 원인으로 예민도가 떨어지는 HRQOL 도구의 사용이나 간 외 요소의 영향의 규명이 불충분한데 기인한다. 본 연구에서는 만성 C형 간염(CHC) 환자에서 약물 중독의 과거력이나 현재의 다른 내과적 질병이나 정신적 질환 등 간 외 질환의 동반여부가 HRQOL score에 영향을 줄 수 있다는 가정에서 시작되었다. 본 연구에서는 기존의 인터페론 치료에 실패했던 107명의 환자를 대상으로 HRQOL을 객관적으로 측정할 수 있는 지표로 질병의 특성에 따른 modified short form (SF-36)과 일반적 건강 척도인 Health Utilities Index (HUI) Mark II/III를 이용하여 HRQOL score에 영향을 줄 수 있는 변수를 조사하였다. sALT, HCV RNA level, HCV genotype, liver histology 등과 같은 간질환의 지표와 인구 통계학적 변수는 HRQOL에 관련이 없었으며, 또한 음주나 정맥주사 약물 남용 및 의존성도 HRQOL score과는 유의한 상관관계가 없었다. 그러나 한가지 혹은 그 이상의 내과질환이 동반되거나, 특히 통증을 동반하는 질환과 치료가 필요한 우울증 같은 정신과적 질환이 modified SF-36과 HUI score에 영향을 주는 것으로 나타났다(p<0.001).
  • 3,472 View
  • 14 Download

Liver Pathology

Billiary Papillomatosis
Young Nyun Park,Chan Il Park
Korean J Hepatol 2001;7(2):222-224.
72세 남자환자는 4년 전 담낭결석으로 진단 받고 약물치료를 받은 과거력이 있으며, 1달간의 우상복부 동통 및 2일간의 고열과 오한을 주소로 내원하였다. MRI 검사상 담관 기원의 종양과 담관의 불규칙한 확장이 관찰되어, 간엽절제술을 시행하였다. 환자의 혈청검사소견은 AST/ALT 20/19 IU/L, alkaline phosphatase 126 IU/L, total bilirubin 0.6 mg/dL, HBsAg(-), anti-HBs(+), anti-HCV(-)였다.
  • 3,539 View
  • 15 Download

Liver Imaging

Inferior Vena Cava Invasion of Hepatocellular Carcinoma
Joon Koo Han
Korean J Hepatol 2001;7(2):225-226.
  • 3,718 View
  • 15 Download

EM Image in Hepatology

The Morphology of Liver through the Electron Microscope (12)
Tae Joong Sohn
Korean J Hepatol 2001;7(2):227-246.
  • 3,426 View
  • 18 Download

Otherses

Two Faces of " Green Juice "
Byung Min Ahn
Korean J Hepatol 2001;7(2):247-251.
  • 3,073 View
  • 19 Download
  • 3,801 View
  • 24 Download